聚焦Evaluate_2026年BiomedtrackerDatamonitor医疗保健Post-EHA报告。Febrile neutropenia was reported in 21.9% of cases, a lower rate than Venclexta’s VIALE-A observation of 42%,suggesting that there was at least no additional toxicity from add-on tuspetinib.
聚焦Evaluate_2026年BiomedtrackerDatamonitor医疗保健Post-EHA报告。Febrile neutropenia was reported in 21.9% of cases, a lower rate than Venclexta’s VIALE-A observation of 42%,suggesting that there was at least no additional toxicity from add-on tuspetinib.
聚焦Evaluate_2026年BiomedtrackerDatamonitor医疗保健Post-EHA报告。Febrile neutropenia was reported in 21.9% of cases, a lower rate than Venclexta’s VIALE-A observation of 42%,suggesting that there was at least no additional toxicity from add-on tuspetinib.
覆盖 2026 年,全文共 139 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了医疗、EHA报告等议题。